Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Assets (2020 - 2025)

BioAtla's Assets history spans 6 years, with the latest figure at $13.8 million for Q4 2025.

  • For Q4 2025, Assets fell 73.62% year-over-year to $13.8 million; the TTM value through Dec 2025 reached $13.8 million, down 73.62%, while the annual FY2025 figure was $13.8 million, 73.62% down from the prior year.
  • Assets reached $13.8 million in Q4 2025 per BCAB's latest filing, down from $15.9 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $277.6 million in Q3 2021 to a low of $13.8 million in Q4 2025.
  • Average Assets over 5 years is $143.0 million, with a median of $165.5 million recorded in 2023.
  • Peak YoY movement for Assets: rose 3.87% in 2021, then tumbled 74.44% in 2025.
  • A 5-year view of Assets shows it stood at $254.4 million in 2021, then decreased by 11.27% to $225.7 million in 2022, then tumbled by 46.99% to $119.7 million in 2023, then tumbled by 56.19% to $52.4 million in 2024, then plummeted by 73.62% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for BCAB's Assets are $13.8 million (Q4 2025), $15.9 million (Q3 2025), and $27.1 million (Q2 2025).